SEC Form SC 13G/A filed by Neogen Corporation (Amendment)
$NEOG
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $15.00 | Buy | Guggenheim |
| 6/16/2023 | $22.00 | Overweight | Wells Fargo |
| 11/22/2022 | Mkt Perform → Outperform | William Blair | |
| 7/12/2022 | $25.00 | Neutral | Piper Sandler |
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00
Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00
William Blair upgraded Neogen from Mkt Perform to Outperform
LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its
Board of Directors expanded in conjunction with the closing of the 3M Food Safety transaction LANSING, Mich., Sept. 12, 2022 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG), a leader in food and animal safety, announced today that it has appointed two new members to its Board of Directors: Jeffrey Capello and Aashima Gupta. The addition of Mr. Capello and Ms. Gupta was agreed by Neogen and 3M Company under the merger agreement for the 3M Food Safety transaction. "We are pleased to add these two experienced industry professionals to Neogen's Board of Directors," said Jim Borel, Neogen's Board Chair. "Their involvement in the global healthcare and biotechnology industries will be a significan
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
LANSING, Mich., Jan. 16, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today the launch of the new Neogen Molecular Detection Assay 2 – Quantitative Salmonella (MDA2QSAL96). The Neogen MDA2QSAL96 kit integrates qualitative pathogen testing solutions and Quantitative Rapid Enrichment Dehydrated (QRED) media designed to enable controlled growth rates for quantitation, allowing poultry producers to verify the effectiveness of their interventions. This quantitative method delivers excellent consistency and sensitiv
Revenue of $231.3 million.Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share.Adjusted Net Income2 of $24.4 million; $0.11 per diluted share.Adjusted EBITDA2 of $51.4 million.Updating full-year guidance.LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the preliminary results of the second quarter ended November 30, 2024. "The second quarter reflected steady progress, as we saw improvement across the business compared to the first quarter, with core revenue growth accelerating in both of our seg
LANSING, Mich., Jan. 7, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) announced today that the Company will participate in two upcoming investor conferences. The Company will participate in the CJS Securities 25th Annual Investor Conference, held virtually on January 14, 2025. John Adent, Neogen's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on January 15, 2025, at 3:45 PM PT. To access the webcast and presentation materials for the J.P. Morgan Healthcare Conference, please visit the Events & Presen
SC 13G - NEOGEN CORP (0000711377) (Subject)
SC 13G - NEOGEN CORP (0000711377) (Subject)
SC 13G/A - NEOGEN CORP (0000711377) (Subject)
10-Q - NEOGEN CORP (0000711377) (Filer)
NT 10-Q - NEOGEN CORP (0000711377) (Filer)
8-K - NEOGEN CORP (0000711377) (Filer)
Revenue of $231.3 million.Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share.Adjusted Net Income2 of $24.4 million; $0.11 per diluted share.Adjusted EBITDA2 of $51.4 million.Updating full-year guidance.LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the preliminary results of the second quarter ended November 30, 2024. "The second quarter reflected steady progress, as we saw improvement across the business compared to the first quarter, with core revenue growth accelerating in both of our seg
LANSING, Mich., Jan. 2, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) announced today that, due to U.S. equity markets being closed in observance of the National Day of Mourning for former U.S. President Jimmy Carter, it will now issue its second-quarter earnings release before the opening of the market on Friday, January 10, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646)
LANSING, Mich., Dec. 19, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its second-quarter earnings release before the opening of the market on Thursday, January 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Corporation Q2 FY25 Earnings Call. The live webcast can be accessed through Neogen's Investor Relation